Tessera Therapeutics
Our Gene Writing™ technology advances genetic medicine beyond its current limitations. Learn more at http://TesseraTherapeutics.com
http://tesseratx.com
201-500 employees
Growth Trajectory
The company shows potential for growth through further development of in vivo programs, particularly focusing on sickle cell disease and T-cell therapies. Their innovation focus on tissue-targeted non-viral delivery technology, combined with addressing major unmet medical needs, positions them well for market expansion. Recent investments also indicate a positive trajectory for developing curative treatments.
Technical Challenges
Tech Stack
Team Size
Key Risks
Reliance on novel technology may present unforeseen technical hurdles and regulatory challenges.
Success depends on the efficacy and safety of in vivo genetic treatments.
Competition from other gene editing and therapy companies could impact market share.
Opportunities
Expanding the application of Gene Writing™ technology to address a wider range of diseases.
Securing partnerships with pharmaceutical companies for commercialization.
Leveraging tissue-targeted non-viral delivery technology for improved treatment outcomes.
Live Data Stream
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats